Compare Prospect Capital Corporation (PSEC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Prospect Capital Corporation trades at $2.14 (market cap $1.08B), while State Street SPDR S&P Biotech ETF trades at $152.12. The key difference: Prospect Capital Corporation pays a 23.26% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Prospect Capital Corporation nearer its low. Which is the better fit depends on your goals.
| PSEC | XBI | |
|---|---|---|
Market Cap | $1.08B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $3.47 | $164.28 |
52-Week Low | $2.15 | $85.16 |
Dividend Yield | 23.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prospect Capital Corporation (PSEC) trades at $2.15, down 4.44% on the day, reflecting persistent bearish technical signals. The company's fundamentals are challenged, with negative revenue of -$407M and a net income margin of -495.94% for 2025, though it has beaten EPS estimates for the last three consecutive quarters. Recent corporate actions include regular dividend payments, while news highlights portfolio activity and deep discounts to net asset value.
The outlook remains cautious due to weak profitability and a bearish analyst consensus. The primary opportunity lies in the stock's high yield and significant discount to book value, but risks include ongoing revenue volatility, declining net asset value, and skepticism about portfolio quality. Investors should weigh income potential against fundamental deterioration.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
